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BACKGROUND: The purpose of this work was to determine the efficacy of inhibiting mammalian target of rapamycin (mTOR) in
pancreatic cancer preclinical models and translate preclinical observations to the clinic.
METHODS: Temsirolimus (20mgKg
 1 daily) was administered to freshly generated pancreatic cancer xenografts. Tumour growth
inhibition was determined after 28 days. Xenografts were characterised at baseline by gene expression and comparative genomic
hybridisation. Patients with advanced, gemcitabine-resistant pancreatic cancer were treated with sirolimus (5mg daily). The primary
end point was 6-month survival rate (6mSR). Correlative studies included immunohistochemistry assessment of pathway expression
in baseline tumours, drug pharmacokinetics (PKs), response assessment by FDG-PET and pharmacodynamic effects in peripheral-
blood mononuclear cells (PBMCs).
RESULTS: In all, 4 of 17 xenografts (23%) responded to treatment. Sensitive tumours were characterised by gene copy number
variations and overexpression of genes leading to activation of the PI3K/Akt/mTOR pathway. Activation of p70S6K correlated with
drug activity in the preclinical studies. Sirolimus was well tolerated in the clinic, showed predictable PKs, exerted pathway inhibition in
post-treatment PBMCs and resulted in a 6mSR of 26%. No correlation, however, was found between activated p70S6K in tumour
tissues and anti-tumour effects.
CONCLUSION: Sirolimus activity in pancreatic cancer was marginal and not predicted by the selected biomarker.
British Journal of Cancer (2010) 103, 649–655. doi:10.1038/sj.bjc.6605819 www.bjcancer.com
Published online 27 July 2010
& 2010 Cancer Research UK
Keywords: pancreatic cancer; mTOR; p70S6K; temsirolimus; sirolimus
                                                           
Pancreatic cancer remains one of the most deadly cancers, ranking
among the top causes of cancer-related deaths (Jemal et al, 2009).
One of the reasons underlying the poor prognosis of this disease is
the lack of effective systemic treatments. Patients with advanced
pancreatic cancer are managed with gemcitabine-based combina-
tion chemotherapy with limited success (Moore et al, 2007).
Attempts to develop new drugs in pancreatic cancer have, in
general, focused on combination studies with gemcitabine, with
very few single-agent screening trials being performed. Indeed,
patients with gemcitabine-resistant disease have traditionally been
considered too sick to participate in clinical trials and have been
managed with palliative care. More recently, however, several
phase II studies have shown that selected patients with gemcita-
bine-resistant pancreatic cancer can be safely treated with second-
line chemotherapy (Gebbia et al, 2007; Kulke et al, 2007;
Xiong et al, 2008; Wolpin et al, 2009). This observation
opens the opportunity to test new agents in refractory patients
in single-agent phase II studies. However, strategies to select
potentially active drugs and candidate biomarkers for a more
effective clinical development are needed.
The mammalian target of rapamycin (mTOR) pathway has
emerged as an important candidate pathway for drug development
(Rubio-Viqueira and Hidalgo, 2006; Meric-Bernstam and Gonza-
lez-Angulo, 2009). In recent years, several inhibitors of this
pathway have been developed in cancer and some compounds
have been approved for selected indications. The mTOR is
downstream in the PI3K/Akt signalling pathway and is activated
in response to growth factor receptor activation and nutrient
stimulation. The mTOR regulates p70S6K and 4EBP1, having an
important role in cell-cycle control and cell proliferation.
Pancreatic cancer is characterised by several key genetic altera-
tions such as activating mutations in the KRAS oncogene or
inactivation in the CDKN2A/INK4A tumour suppressor gene that
result in abnormal cell signalling and altered control of cell
proliferation (Jones et al, 2008). Thus, pancreatic cancer is, in
principle, an attractive tumour type to test mTOR inhibitors, and
indeed, preclinical studies in established pancreatic cancer cell
lines support this notion (Grewe et al, 1999; Agbunag and Bar-Sagi,
2004; Ito et al, 2006).
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sWe have developed a set of freshly generated pancreatic cancer
xenografts as a preclinical platform for preclinical screening and
biomarker discovery in pancreatic cancer (Rubio-Viqueira et al,
2006). These tumours, which have been extensively characterised,
represent the heterogeneity of the disease and retain the most
important genetic features of the originator tumour (Rubio-
Viqueira et al, 2006; Rubio-Viqueira and Hidalgo, 2009). In this
study, we explored the activity of mTOR inhibition in pancreatic
cancer with the goals to determine whether the observed activity
warranted clinical development and to prioritise biomarkers that
could be incorporated in clinical trials.
MATERIALS AND METHODS
Xenograft studies
Direct pancreatic cancer xenografts were generated as previously
reported (Rubio-Viqueira et al, 2006). In this study we used
17 xenografts from the Hopkins PancXenoBank collection.
Temsirolimus (Torisel, Wyeth Pharmaceuticals, Philadelphia, PA,
USA) was administered intraperitoneally at 20mgKg
 1 daily for 28
days as previously reported (Ito et al, 2006). Tumour size was
evaluated two times per week by caliper measurements using the
following formula: Tumour volume¼(length width
2)/2. Relative
tumour growth inhibition/regression was calculated as
T/C¼(Ti T0/Ci C0), Ti and Ci represent tumour size of treatment
and control group at the end of experiments, respectively; T0 and
C0 represent tumour size at initiation of experiments, respectively.
T/C40 represent growth inhibition, T/Co0 represents tumour
regression. The research protocol was approved by the Johns
Hopkins University Animal Care and Use Committee, and animals
were maintained in accordance to guidelines of the American
Association of Laboratory Animal Care.
Microarray gene expression and array CGH profiling
Xenografts were profiled at baseline for gene expression using
Affymetrix U133 Plus 2.0 gene arrays (Santa Clara, CA, USA) in
duplicates as reported (Jimeno et al,2 0 0 8 c ) .S i m i l a r l y ,a r r a yc o m p a -
rative genomic hybridization (CG H )w a sc a r r i e do u ta sd e s c r i b e d
(Barrett et al, 2004). Briefly, genomic DNA from normal and pancreatic
cancer xenografts was fragmented and labelled according to published
protocols (Wu et al, 2005). Labelled DNAs were hybridised to human
Agilent 44A CGH microarrays consisting of B40000 oligonucleotide
probes (Agilent Technologies, Palo Alto, CA, USA) and scanned on an
Agilent DNA microarray scanner. Raw log2 ratio data were calculated
using Agilent Feature Extraction 9.1 software.
Gene set enrichment analysis
Gene set analysis was performed using the Gene set enrichment
analysis (GSEA) software V2.0.2 (http://www.broad.mit.edu/gsea)
(Subramanian et al, 2005). Genes represented by more than one
probe were collapsed using the Collapse Probes utility to the probe
with the maximum value. Gene set permutations were performed
500 times for each analysis, and the pathway/gene set list is sorted
by the Normalized Enrichment Score. We used the pathways
defined by the Kyoto Encyclopedia of Genes and Genomes (KEGG)
database to determine the rank-ordered pathway list for the
xenografts. Human pathway annotations were downloaded from
KEGG (August 2007 release), and 166 gene sets passed the gene set
size filter criteria (min¼10, max¼500).
ELISA
Levels of phosphorylated p70S6K were quantified at baseline using
a solid-phase sandwich ELISA as per manufacture instructions
(Immunoassay Kit, cat. no. KHO0581, Invitrogen, Camarillo, CA, USA).
Clinical study
Patients with advanced pancreatic adenocarcinoma refractory
to gemcitabine were eligible for this trial. Patients were required
to have unidimensionally measurable disease and tumour tissue
for immunohistochemistry (IHC) assessment or willingness to
undergo a safe tumour biopsy. Other eligibility criteria included an
Eastern Cooperative Oncology Group performance score 0–1,
adequate haematological, renal and liver functions, including an
absolute neutrophil count 41500 cells per mm
3, haemoglobin
49g per 100ml, serum creatinine p2mg per 100ml, bilirubin
p2mg per 100ml, ALT, AST, alkaline phosphatase p5 times the
upper limit of normal and triglycerides and total cholesterol o2
times the upper limit of normal.
Sirolimus was administered at a single oral flat dose of 5mg per
day continuously in an outpatient setting. A treatment cycle was of
28 days. Patients with grade 3 or 4 adverse events related to the
study drug temporarily discontinued the treatment. They were
asked to resume treatment on resolution of the toxic event to grade
0 or 1 at a reduced dose of 4mg per day. Patients experiencing
second grade 3 or 4 toxicity were to undergo a second dose
reduction to 3mg per day. In addition, patients who experienced
symptomatic grade 2 toxicities or biochemical toxicity persisting
for longer than 1 week had their daily dose of rapamycin decrease
by one dose level to 4mg per day. Patients requiring more than
two dose reductions were taken off study. Patients had complete
blood count and chemistry tests performed at baseline and every
week for the first cycle and at every other week thereafter. Toxicity
was graded according to the National Cancer Institute Common
Toxicity Criteria for Adverse Events Version 3.0. Response
to treatment was measured using FDG-PET-CT scan for every
other cycle.
Pharmacokinetic sampling, analytical assay and data
analysis
Pharmacokinetic studies were performed after single and multiple
doses during cycle 1 on days 1 and 28. Whole blood was collected
in EDTA-containing tubes pre-treatment and at 1, 2, 4 and 6h
post-treatment on days 1 and 28. Trough samples were collected
before drug administration on days 2, 3, 8, 15 and 22 of the first
cycle and on day 1 of the second cycle. Samples were stored at
 701C or below. Sirolimus concentrations in whole blood were
determined over a range of 0.5–200ngml
 1 by a validated high-
performance liquid chromatography with mass spectrometry
detection (LC/MS/MS) method. Individual pharmacokinetic (PK)
parameters were estimated by standard noncompartmental
analysis using WINNonlin (Scientific Consultant, Apex, NC,
USA) version 5.0 (Pharsight, Mountain View, CA, USA) (Gibaldi,
1982).
Inmunohistochemistry of baseline tumour samples
Immunohistochemical labelling was performed using standard
methods. Formalin-fixed 5mm slides from paraffin-embedded
tissue were deparafinised and stained with anti-phospho-p70S6K
(Thr389) mouse monoclonal antibody (Cell Signaling Technolo-
gies). Immunolabelling was detected as per kit instructions
(Ventana IVIEW Detection Kits, cat. no. 760091, Ventana). The
intensity of the staining was determined using H-scores, a
composite measure of intensity   proportion of staining cells.
Correlative studies in peripheral-blood mononuclear cells
Levels of total and phosphorylated [pT389] p70S6K in peripheral-
blood mononuclear cells (PBMCs) at baseline and at 6h after the
first sirolimus dose were quantified using a solid-phase sandwich
ELISA as per manual instructions (Invitrogen Immunoassay kit,
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scat. no. KHO0581). The ratio of phospho/total p70S6K at 6h after
the first dose of sirolimus was normalised to baseline level and
expressed as a percentage.
Statistical considerations
The primary end point of the clinical trial was the proportion
of patients surviving at 6 months after treatment commencement
(6-month survival rate (6mSR)). The expected 6mSR with standard
of care in the second-line setting is 30%, and on the basis of the
preclinical study, a 25% positive outcome was expected (Rothen-
berg et al, 1996). The sample size was determined to detect an
improvement in 6mSR from 30 to 50%. With 31 patients enroled
and a one-side a of 0.05, the study has a 76% power to detect this
difference. The secondary objectives included: (a) to evaluate the
relationship between baseline phospho-p70S6K expression by IHC
and clinical outcome; (b) to characterise the toxicity and PKs of
sirolimus in this patient population and; (c) to determine the
pharmacodynamic effects of the agent on p70S6K activation in
PBMCs. To test whether activation of PI3K/Akt/mTOR pathway
was correlated with survival in patients treated with sirolimus, a
Fisher’s exact test was performed to determine the relation
between phospho-p70S6K levels at baseline and 6mSR. Differences
between PK parameters during sampling periods were compared
by a Wilcoxon matched-pairs signed-rank test. All PK parameters
are reported as mean±standard deviation unless otherwise noted.
Pearson’s correlation coefficient or Mann–Whitney U-tests were
used to assess correlations between exposure (Cmax or AUC) and
exploratory PD end points (that is, PBMC phospho-p70S6K,
survival and PET-CT response). These tests were performed using
JMP Statistical Discovery software (version 4.0.4; SAS Institute,
Cary, NC, USA) or SPSS version 16 (SPSS, Chicago, IL, USA).
RESULTS
Tumour growth inhibition with temsirolimus in direct
pancreatic cancer xenografts correlated with pathway
activation
We observed tumour regression in four xenografts treated with
temsirolimus (Figure 1). Assessment of gene copy number
variations in these tumours by CGH array showed gene copy
number variations that could potentially lead to PI3K/Akt/mTOR
pathway activation. Xenografts Panc219 and Panc198 had focal
gains in NRAS and KRAS, respectively, whereas Panc266 and
Panc287 had a homozygous deletion of FHIT or PTEN, respectively
(Figure 2A). These genetic abnormalities were not, however,
specific because some of the resistant tumours also had similar
genetic alterations such a FHIT losses and AKT amplification.
Supplementary Table 1 summarises the genomic alterations
observed in these tumours.
To gain further insight into gene pathways that might predict
response to temsirolimus, we performed GSEA on the gene
expression profiles of both sensitive and resistant cases. From the
GSEA results, there were 8 and 18 pathways with Po0.01 and false
discovery rate o20% enriched in the sensitive and resistant cases,
respectively (Table 1). Five cancer (chronic myeloid leukaemia,
glioma, pancreatic, prostate and renal cell cancer) pathways were
among the pathways enriched in the sensitive cases. We found 32
common core genes that were upregulated in more than two
pathways enriched in the sensitive cases (Supplementary Table 2).
Many of these common core genes (AKT3, BRAF, EGFR, FGFR1,
IGF1R, PIK3CA, PIK3R3, PDGFA and PDGFB) were related to the
PI3K/Akt/mTOR pathway.
To further explore whether those genetic changes result in
pathway activation, we measured phospho-p70S6K in the 17
xenografts using an ELISA test as a downstream read out of
pathway activation. As shown in Figure 2B, there was a significant
correlation between tumour regression after treatment with
temsirolimus and baseline activation of p70S6K.
From these studies, we concluded that mTOR inhibitors exerted
distinct anti-tumour effects in pancreatic cancer xenografts that
were characterised by heightened activation of the PI3K/Akt/
mTOR pathway. To validate this hypothesis, we conducted a phase
II trial with the mTOR inhibitor sirolimus in patients with
advanced pancreatic cancer, integrating measurement of phospho-
p70S6K activation as a predictor of response.
General clinical results
A total of 31 patients, whose pertinent characteristics are listed in
Table 2, were enroled in this trial. All patients had previously
progressed to a gemcitabine-containing regimen, including 22
patients who had received previous chemotherapy for metastatic
disease.
Overall treatment was well tolerated. The principal toxicities are
summarised in Figure 3. Most of the adverse events were grade 1
(67%), 24% were grade 2, 9% were grade 3 and there was no grade
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Figure 1 Tumour growth inhibition (T/C) in 17 direct pancreatic cancer xenografts treated with temsirolimus. Four xenografts showed tumour regression
(negative T/Cs). Bars represent standard deviation.
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s4 adverse events. The most common grade 3 adverse event was
hyperglycaemia, observed in 10% of the patients. Although 22
(75%) patients had already received chemotherapy for metastatic
disease before inclusion in this study, only one patient developed a
grade 3 haematological adverse event (neutropenia). One patient
developed a grade 3 increase in AST/ALT levels on cycle 1, day 15;
treatment was stopped for 1 week with subsequent normalisation
of liver function tests. One patient was admitted because of grade 3
enterocolitis on cycle 1, day 6; treatment was discontinued and the
patient was discharged 4 days later. Other grade 3 toxicities were
hyponatremia and rash in one patient (3%) each.
There were no objective responses in this trial. Four patients
(13%) had stable disease (SD) at the 2-month follow-up evaluation.
The 6mSR for the overall population was 26% (95% CI 13–45%;
Supplementary Figure 1).
PI3K/Akt/mTOR/pathway activation and clinical outcome
We assessed baseline levels of phospho-p70S6K in 22 out of 31
patients. In contrast to the preclinical findings, there was no
correlation between baseline levels of phospho-p70S6K by IHC and
clinical outcome.
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Figure 2 (A) Sensitive xenografts had focal gains in RAS, or homozygous deletions in PTEN or FHIT, potentially leading to pathway activation. Red colour
represents gene copy number gains. Green colour represents gene copy number losses. (B) Tumour regression after treatment with temsirolimus in direct
pancreatic cancer xenografts was correlated with baseline phospho-p70S6K. Green dots represent xenografts that experienced tumour regression after
temsirolimus treatment. Red dots represent xenografts that experienced tumour growth.
Table 1 Gene pathways enriched in temsirolimus-sensitive and -resistant xenografts as per KEGG classification
Name KEGG pathway Size NES P FDR
Pathways enriched in the sensitive cases (Po0.01)
HSA03010 Ribosome 54 2.41 0.000 0.00
HSA05220 Chronic myeloid leukaemia 76 1.86 0.000 0.04
HSA04520 Adherens junction 79 1.83 0.000 0.03
HSA05214 Glioma 64 1.74 0.000 0.06
HSA05212 Pancreatic cancer 73 1.68 0.000 0.08
HSA05215 Prostate cancer 88 1.58 0.008 0.14
HSA04350 TGF-b signalling pathway 87 1.57 0.000 0.13
HSA05211 Renal cell carcinoma 69 1.52 0.007 0.15
Pathways enriched in the resistant cases (Po0.01)
HSA00590 Arachidonic acid metabolism 52  1.97 0.000 0.00
HSA00260 Glycine, serine and threonine metabolism 45  1.97 0.000 0.00
HSA00591 Linoleic acid metabolism 35  1.85 0.000 0.02
HSA00280 Valine, leucine and isoleucine degradation 43  1.80 0.000 0.03
HSA03320 PPAR signalling pathway 66  1.78 0.000 0.03
HSA00910 Nitrogen metabolism 23  1.77 0.006 0.03
HSA00252 Alanine and aspartate metabolism 32  1.76 0.000 0.03
HSA00450 Selenoamino acid metabolism 28  1.75 0.000 0.03
HSA00051 Fructose and mannose metabolism 42  1.66 0.009 0.07
HSA00710 Carbon fixation 22  1.62 0.009 0.08
HSA00062 Fatty acid elongation in mitochondria 10  1.62 0.010 0.08
HSA00970 Aminoacyl-tRNA biosynthesis 37  1.59 0.006 0.10
HSA00620 Pyruvate metabolism 42  1.58 0.009 0.10
HSA00562 Inositol phosphate metabolism 50  1.58 0.003 0.09
HSA00650 Butanoate metabolism 44  1.54 0.009 0.12
HSA00010 Glycolysis/gluconeogenesis 62  1.49 0.009 0.16
HSA04020 Calcium signalling pathway 175  1.47 0.008 0.17
HSA04080 Neuroactive ligand–receptor interaction 251  1.46 0.003 0.17
Abbreviations: FDR¼false discovery rate; KEGG¼Kyoto Encyclopedia of Genes and Genomes; NES¼normalized enrichment score; P¼P-value; TGF¼transforming
growth factor.
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PK data were evaluable in 30 patients. The PK profile of sirolimus
was characterised by rapid absorption and a slow elimination
phase after oral administration. By assessment of pre-treatment
trough concentrations, steady state was reached by day 8.
Accumulation was noted as there was an increase in sirolimus
exposure (Cmax 15.5±9.2ngml
 1 (n¼30) vs 24.8±10.4ngml
 1
(n¼20) from day 1 to day 28; and day 1 AUCinf 234.5±
121.5nghml
 1 (n¼22) vs day 28 AUC0–24h388.6±129.1nghml
 1
(n¼15); (Po0.05)). There was a statistically significant increase in
the day 28 half-life (10.63±2.57h (n¼22) vs 20.67±5.12h (n¼14)
on days 1 and 28, respectively; Po0.05) and decrease in the
apparent systemic clearance (28.6±17.3lh
 1 (n¼22) vs
13.6±4.0lh
 1 (n¼14) on days 1 and 28, respectively; Po0.05).
Sirolimus showed extensive distribution in excess of blood volume
(Vz/F 414.6±206.8l (mean±s.d.; n¼22) and 415.7±200.4l
(n¼14) on days 1 and 28, respectively). The steady-state pre-
treatment trough concentration was 12.6±5.1ngml
 1 (n¼28). No
correlation was found between PK parameters clinical outcome and
PD markers.
PD evaluation
Patients with SD, as shown by PET-CT, had statistically
significantly greater inhibition of p70S6K in PBMC at 6h after
treatment, as shown by a higher decrease in the ratio of phospho/
total p70S6K (35 vs 63; P¼0.01). Thus, activated phospho-p70S6K
levels at 6h were predictive for PET-CT response at 8 weeks
(Figure 4).
DISCUSSION
This study aimed to determine the therapeutic role of inhibiting
mTOR in preclinical models of pancreatic cancer and in patients
with this disease. The mTOR inhibitor, temsirolimus, induced
tumour regressions in 4 of 17 (23%) freshly generated pancreatic
cancer xenografts that were, in conjunction, characterised by
genetic alterations, leading to an increased activation in the
PI3K/Akt/mTOR pathway. As a single agent, sirolimus resulted in a
26% 6mSR in patients with previously treated pancreatic cancer,
but did not result in tumour regressions in any patients. Contrary
to our hypothesis, there was no indication that patients with higher
activation of the pathway, as measured by the selected biomarker
in this trial, did better.
The role of preclinical models in cancer drug development
continues to evolve. In the era of cytotoxic agents, models were
used to show tumour growth inhibition in a randomly selected
group of rapidly growing xenograft models (Berger et al, 1990).
More recent efforts, however, include testing agents in larger
collection of xenografts representing a disease of interest, not only
to gauge potential activity but also to understand predictors of
efficacy (Perez-Soler et al, 2000; Rubio-Viqueira et al, 2006;
Table 2 Patient’s characteristics
Characteristics Number Percentage
Age (years)
Median 64
Range 39–77
Sex
Male 21 68
Female 10 32
ECOG PS
01 2 3 9
11 9 6 1
Type of surgery
Whipple 11 35
Pilorus preserving 4 13
No previous surgery 16 52
Previous perioperative chemoradiation 11
Previous perioperative chemotherapy 4
Previous chemotherapy for metastatic disease
GEM-Tarceva 6 25
GEM 5 21
GEM-XELODA 3 12.5
GEM-CDDP 3 12.5
GEM-LOHP 3 12.5
GEM-CPT11 1 4
GEM-XELODA-Txt 1 4
GEM-Avastin 1 4
XELODA-Avastin-Tarceva 1 4
Serum Ca 19-9 (Uml
 1)
Median 11048
Range 4–82808
Abbreviations: CDDP¼cisplatin; CPT-11¼irinotecan; ECOG PS¼Eastern Cooperative
Oncology Group performance score; GEM¼gemcitabine; LOHP¼oxaliplatin; Txt¼
taxotere.
Grade 1
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Grade 3
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Nausea
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Diarrhea
Anaorexia
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Figure 3 Treatment-related toxicities (n¼31).
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Figure 4 Activity of p70S6K at 6h after first dose of sirolimus predicts
stable disease on PET-CT evaluation. Patients with stable disease as shown
by PET-CT on restaging at 8 weeks had greater inhibition of phospho-
p70S6K in PBMC at 6h than those with disease progression (P¼0.01).
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sHoughton et al, 2007; Jimeno et al, 2008a). With this goal in mind,
we and others have started conducing large-scale phase II-like
preclinical studies in pancreatic cancer. In this work, we followed
such an approach to test the activity of mTOR inhibitors in
pancreatic cancer.
One important consideration in this work, however, is that the
level of activity in preclinical models that predict clinical efficacy is
not established. Classically, a T/C of 40% has been considered
supportive of anti-tumour efficacy and used as a threshold to
move drugs to the clinic. This criterion, in our opinion, is too
unrestrictive and overestimates the expected clinical results.
Indeed, if one applies the commonly used RECIST clinical criteria
of response, a T/C of 40% would be disease progression. We have
therefore applied a more restrictive criterion and consider activity
if there is a tumour regression. The current situation is that there
are thousands of anti-cancer agents available but yet very little
work in the clinic. A more selective preclinical approach is needed
to prioritise which drugs to develop in patients. Efforts to better
establish levels of preclinical efficacy that predict positive clinical
outcome are, indeed, needed.
Another important, and not established, question is which level
of preclinical activity is required to justify conducting a clinical
trial. It is remarkable to note the important parallelisms between
the preclinical and clinical study with B25% cases meeting the
pre-specified primary objective in both studies. Notwithstanding
that our patients were very heavily pretreated, a 25% 6mSR in the
second-line pancreatic cancer is low and does not warrant
further development of this drug as a single agent in this
disease unless a predictive biomarker is identified. This has been
indeed the finding of another recently published trial (Wolpin
et al, 2009). In retrospect, we should have established a higher
threshold of activity in the preclinical study before advancing the
agent to clinical development. Given the larger number of available
agents in clinical development and the limited resources, we
propose that only agents with preclinical activity significantly
greater than the clinical activity of interest are selected for clinical
development.
The second major goal of this work was to identify biomarkers
of activity. The preclinical data show that tumour regression after
treatment with temsirolimus was limited to xenografts with high
activation of the PI3K/Akt/mTOR pathway, as shown by high
activation of p70S6K. There is a whole body of literature
supporting the role of PTEN losses in activation of the PI3K/
AKT/mTOR pathway in a variety of tumours including prostate,
breast and glioma (Li et al, 1997). Our finding that 1 of 17 (5%)
xenografts had PTEN deletion is in consonance with previous
evidence that PTEN losses are infrequent in pancreatic cancer
(Okami et al, 1998). The fragile histidine triad (FHIT) gene, a
tumour suppressor, is lost in most malignancies, including
pancreatic cancer (Simon et al, 1998; Huebner and Croce, 2001).
Loss of FHIT, leads to increase AKT activity both in vitro and
in vivo (Semba et al, 2006). These findings are supported by the
results from the GSEA, showing that sensitive xenografts were
enriched in pathways with high content of genes involved in the
PI3K/Akt/mTOR pathway. Thus, the striking correlation between
the drug activity and pathway activation, as measured by phospho-
p70S6K, a downstream mediator of the pathway, is expected on the
basis of the current knowledge of this pathway.
Although the overall level of activity of mTOR inhibitors in
pancreatic cancer was modest, the finding that the activity could be
linked to a biomarker was critical to support the conduction of the
clinical study. If the 25% of patients who are sensitive can be
identified upfront, the clinical development of the drug in pancreas
cancer is feasible and likely to be successful. Unfortunately, we did
not observe such a relationship in the clinical trial. Several factors
can be considered to explain this issue. First, it could be that the
concentrations of sirolimus achieved in patients are inferior to
those achieved in mice. However, we have used the maximum
tolerated dose of sirolimus based on data from a previous phase I
study published by our group (Jimeno et al, 2008b). Second, PDA
is characterised by an intense desmoplastic reaction that may lead
to decreased intratumoural concentrations of sirolimus and
thus explain lack of activity (Olive et al, 2009). Third, it could be
that the biomarker selected, that is, activation of p70S6K, is not
valid. We doubt, however, this is the reason. The notion that
activation of the PI3K/Akt/mTOR pathway leads to p70S6K
activation is supported by multiple studies (Hennessy et al,
2005; Riemenschneider et al, 2006). In addition, several trials with
mTOR inhibitors suggest that this is a candidate marker (Galanis
et al, 2005; Cloughesy et al, 2008). More likely, the negative results
are because of trial design and technical reasons. We have used an
IHC technique applied to archival tissues and we really do not
know the preservation of the phosphorylated antigen over time in
these materials. This is a recurrent problem in clinical trials that
relay on archival tissue for which no satisfactory solution has been
proposed. In addition to this, other investigators have questioned
the performance of the specific antibody we used (anti-Thr389
S6K) for reliable quantification of the activity of p70S6K on
paraffin sections (Cloughesy et al, 2008). We assessed p70S6K in
primary tumours and treated metastatic disease. We do not know
whether the process of generating tumour metastasis results in
variations in this biomarker. In retrospect, a better strategy would
have been to perform a fresh biopsy from a metastatic site and to
use the same ELISA method that we have used in the preclinical
study. It is clear that this approach adds morbidity, complexity and
costs, but it may at the end be the only strategy to answer these
questions. Finally, it could just mean that the preclinical model is
not predictive at all of clinical activity and what is learnt in one
does not predict what happens in the other.
In summary we have integrated a preclinical and clinical trial of
mTOR inhibitors in pancreatic cancer. The agent resulted in
B25% of cases achieving a positive response. In the preclinical
study, activity was linked to pathway activation. This finding,
however, was not observed in the clinic. The most likely
explanation for this negative result is technical in nature, but
other factors cannot be ruled out. In the absence of a well-defined
biomarker to select patients, the overall level of activity does not
suggest that these drugs as single agents would be effective in this
disease.
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